Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.

NCT07177937 is registered in ClinicalTrials.gov with Hangzhou DAC Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07177937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07177937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.
Lead sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 3, 2026
Completion date
October 20, 2030
Enrollment
150 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, other advanced solid tumors, prostate cancer, small cell lung cancer